EPRONTIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPRONTIA (EPRONTIA).
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting presynaptic serotonin reuptake.
| Metabolism | Primarily hepatic via CYP2D6; active metabolite norfluoxetine; extensive first-pass metabolism. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% metabolized hepatically; metabolites are also renally excreted. Fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is 20–30 hours in adults with normal renal function; prolonged to 40–60 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment. |
| Protein binding | 15–20% bound to plasma proteins (primarily albumin); binding is concentration-independent. |
| Volume of Distribution | Apparent volume of distribution is 0.7–0.9 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Oral bioavailability is 100% following tablet or capsule administration; no significant first-pass metabolism. |
| Onset of Action | Oral: 1–2 hours for detectable serum concentrations; peak anticonvulsant effect occurs after 4–6 hours due to slow CNS penetration. |
| Duration of Action | Maintenance of anticonvulsant effect over 24 hours with once-daily dosing; steady-state achieved in 5–7 days. |
Adults: 200-800 mg twice daily orally, starting at 200 mg twice daily, increasing by 200 mg/day weekly to maintenance.
| Dosage form | SOLUTION |
| Renal impairment | CrCl ≥50 mL/min: no adjustment. CrCl 30-49 mL/min: 200-400 mg twice daily. CrCl <30 mL/min: 200-400 mg once daily. Hemodialysis: 200-400 mg once daily; supplementary dose of 50-100 mg after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: initial dose 100 mg twice daily, titrate slowly. Child-Pugh Class C: not recommended. |
| Pediatric use | Children 6-17 years: initial 25-50 mg/kg/day orally in two divided doses, titrate to maintenance 100 mg/kg/day (max 4000 mg/day). |
| Geriatric use | Start at 200 mg twice daily; titrate slowly due to reduced renal clearance; monitor for dizziness and somnolence. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPRONTIA (EPRONTIA).
| Breastfeeding | Topiramate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.69-0.86. The relative infant dose is estimated at 10-20% of the maternal weight-adjusted dose. Breastfeeding is generally considered acceptable with caution, particularly in low maternal doses and when monitoring the infant for drowsiness, poor feeding, or weight loss. However, potential risks include irritability and hypotonia. The American Academy of Pediatrics considers topiramate compatible with breastfeeding, but long-term neurodevelopmental effects are not fully assessed. |
| Teratogenic Risk | EPRONTIA (topiramate) is associated with an increased risk of oral clefts (cleft lip with or without cleft palate) in infants exposed during the first trimester. The risk is dose-dependent and higher with doses >200 mg/day. Data from the North American Antiepileptic Drug Pregnancy Registry indicate a prevalence of oral clefts of approximately 4.8 per 1,000 live births among topiramate-exposed pregnancies, compared to a background rate of 1-2 per 1,000. In the second and third trimesters, topiramate may cause intrauterine growth restriction (IUGR), low birth weight, and potential neurodevelopmental effects. The drug crosses the placenta, and fetal plasma concentrations are similar to maternal levels. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Concomitant use with MAOIs or within 14 days of discontinuing; concomitant use with pimozide or thioridazine; known hypersensitivity to fluoxetine or any component.
| Precautions | Serotonin syndrome; discontinuation syndrome; activation of mania/hypomania; seizures; angle-closure glaucoma; bleeding risk; hyponatremia; use in hepatic impairment; pregnancy category C; QT prolongation. |
Loading safety data…
| Fetal Monitoring | Maternal monitoring: Serum topiramate levels should be monitored periodically during pregnancy due to altered pharmacokinetics; target trough levels of 2-5 mcg/mL are typical but individualized. Fetal monitoring: Level 2 ultrasound at 18-20 weeks to evaluate for oral clefts and other anomalies. Fetal growth assessments by ultrasound every 4-6 weeks in second and third trimesters to detect IUGR. Consider nonstress testing or biophysical profile in third trimester for high-risk pregnancies. Postnatal monitoring: Assess neonate for signs of drug withdrawal (e.g., hyperexcitability, jitteriness, poor feeding) and metabolic disturbances (e.g., metabolic acidosis). |
| Fertility Effects | Topiramate does not have established direct effects on fertility in humans. In animal studies, topiramate caused menstrual cycle irregularities and impaired fertility at high doses. In women, topiramate has been associated with menstrual irregularities and anovulation due to alterations in hypothalamic-pituitary-ovarian axis, possibly via GABAergic effects or weight loss. However, data are limited and fertility impact is considered minimal at therapeutic doses. |